Is GlaxoSmithKline plc a better dividend buy than Standard Life plc and Legal & General Group plc?

Does a lack of dividend growth hold back GlaxoSmithKline plc’s (LON: GSK) income appeal versus Standard Life plc (LON: SL) and Legal & General Group plc (LON: LGEN)?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

While GlaxoSmithKline (LSE: GSK) has a relatively high yield of 5.5%, one concern among investors is its lack of forecast dividend growth. In fact, the health care company is expected to keep dividends at their current level over the next couple of financial years as it seeks to reinvest for future growth and to also increase its dividend coverage ratio.

Both of these uses of cash seem to be perfectly sound and should help to improve the company’s long-term profit growth prospects. However, it means that GlaxoSmithKline’s investors are unlikely to see their income growth beat inflation and if inflation spikes then this could be a worry.

However, beyond the next couple of years, GlaxoSmithKline looks set to grow shareholder payouts at a rapid rate. That’s at least partly because it has an excellent pipeline of new drugs, with around 40 treatments having the potential to improve the company’s bottom line. And with its consumer goods segment offering stability, GlaxoSmithKline seems to offer the perfect mix of dividend growth potential, stability and a high yield.

Passive income stocks: our picks

Do you like the idea of dividend income?

The prospect of investing in a company just once, then sitting back and watching as it potentially pays a dividend out over and over?

If you’re excited by the thought of regular passive income payments, as well as the potential for significant growth on your initial investment…

Then we think you’ll want to see this report inside Motley Fool Share Advisor — ‘5 Essential Stocks For Passive Income Seekers’.

What’s more, today we’re giving away one of these stock picks, absolutely free!

Get your free passive income stock pick

Fast dividend growth?

Of course, it’s not the only company with excellent income prospects. Diversified financial services companies Standard Life (LSE: SL) and Legal & General (LSE: LGEN) both have excellent yields and could grow dividends at a faster rate than even GlaxoSmithKline in the long run.

For example, Standard Life currently yields 5.9% and with dividends forecast to rise by over 7% next year, it could become increasingly popular among income-seeking investors. Furthermore, with dividends being covered 1.35 times by profit, there seems to be sufficient headroom to increase dividends at a faster rate than profit over the coming years. And with Standard Life forecast to grow its bottom line by 10% next year, there’s the potential for a double-digit increase in dividends over the medium term.

Similarly, Legal & General offers a high yield and upbeat dividend growth prospects. It currently yields 6.1% and with dividends being covered 1.4 times by profit, there’s scope for a rapid rise in shareholder payouts in future. Plus, with Legal & General having increased dividends per share by 120% over the last five years, it has an excellent track record when it comes to rewarding shareholders with higher dividends.

Glaxo resilience

However, while Standard Life and Legal & General are top-notch income stocks, GlaxoSmithKline appears to be more appealing. That’s because it has lower positive correlation with the wider economy than is the case for its index peers and this means that dividends are unlikely to come under the same degree of pressure in an economic downturn. In other words, dividends at GlaxoSmithKline may be more resilient in an uncertain economic climate. As such, it seems to be the pick of the three stocks from an income-seeking perspective.

British CEO gobbles up £238,000 of own stock

What company does he run?

And why is he so confident in its long-term potential?

This new report - ‘One Top Growth Stock from The Motley Fool’ - reveals the full details, both risks and opportunities. Some of which you may find frankly, unbelievable.

Though past performance does not guarantee future results, over the past 5 years, it’s seen consistent:

  • Double-digit revenue growth
  • Returns on capital almost 600% the UK average
  • Now, profits are exploding again - up 46% in 1 year!

It’s no wonder insiders are buying this stock hand over fist. Last year, they bought a total £492,000 of shares. And now might be the ideal moment to join them.

So please, don’t miss this report, ‘One Top Growth Stock from The Motley Fool’ Including both risks and opportunities.

Secure your FREE copy now

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Peter Stephens owns shares of GlaxoSmithKline, Legal & General Group, and Standard Life. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Asian man looking concerned while studying paperwork at his desk in an office
Investing Articles

2 reasons why this stock market crash isn’t a repeat of 2020

When the stock market crashed during the Covid-19 pandemic, the recovery was rapid and spectacular. Could the same thing happen…

Read more »

Investing Articles

Car-mageddon! The Aston Martin share price has tanked 30% in a month

Our writer looks at the performance of the Aston Martin share price over the past few weeks and considers whether…

Read more »

Asian man looking concerned while studying paperwork at his desk in an office
Investing For Beginners

I was right about the UK stock impact from the tariff news. Here’s what I think happens next

Jon Smith explains why he warned about the impact of the tariffs on UK stocks and why more short-term pain…

Read more »

Investing Articles

Looking for penny shares? Here’s one I think looks like a terrific bargain to consider!

I think this penny share -- which has almost doubled in value over the last year -- is one of…

Read more »

Investing For Beginners

Why I’m staying away from the Barclays share price even with a 19% drop

Jon Smith explains why he's cautious right now about the Barclays share price, with the potential for lower revenues from…

Read more »

Investing Articles

2 FTSE 100 and FTSE 250 stocks to consider as stock markets plummet!

Looking for lifeboats as growth-crushing trade tariffs loom? Here are two (including a FTSE 100 gold stock) I think merit…

Read more »

Number three written on white chat bubble on blue background
Investing Articles

Just released: the 3 best growth-focused stocks to consider buying in April [PREMIUM PICKS]

Our goal here is to highlight some of our past recommendations that we think are of particular interest today, due…

Read more »

Happy young plus size woman sitting at kitchen table and watching tv series on tablet computer
Investing Articles

£10,000 invested in Watches of Switzerland shares 1 year ago is now worth…

Watches of Switzerland shares have been decimated by Trump’s tariffs on Switzerland. Dr James Fox explores whether this is an…

Read more »